



Published in final edited form as:

*Expert Rev Mol Diagn.* 2015 March ; 15(3): 339–348. doi:10.1586/14737159.2015.1002469.

## Genetic diagnosis and prognosis of Alzheimer's disease: challenges and opportunities

**Christiane Reitz**

Sergievsky Center/Taub Institute/Dept. of Neurology, Columbia University, 630 W 168th Street, Rm 19-308, New York, NY 10032, phone: (212) 305-0865, fax: (212) 305-2391

Christiane Reitz: cr2101@cumc.columbia.edu

### Abstract

Alzheimer's disease (AD), the most common form of dementia in western societies, is a pathologically and clinically heterogeneous disease with a strong genetic component. The recent advances in high-throughput genome technologies allowing for the rapid analysis of millions of polymorphisms in thousands of subjects has significantly advanced our understanding of the genomic underpinnings of AD susceptibility. During the last 5 years, genome-wide association and whole-exome- and whole-genome sequencing studies have mapped more than 20 disease-associated loci, providing insights into the molecular pathways involved in AD pathogenesis and hinting at potential novel therapeutic targets. This review article summarizes the challenges and opportunities of when using genomic information for diagnosis and prognosis of Alzheimer's disease.

### Keywords

Alzheimer's disease; genomics; diagnosis; prognosis; therapy

### EPIDEMIOLOGY OF AD

Late-onset Alzheimer disease (AD) is the most frequent form of dementia affecting 24 million persons worldwide.[1] In the US alone, five million people are affected causing a direct estimated health-care cost of \$215 billion dollars per year.[1,2] The annual incidence rate of AD increases from 1% among people aged 65 years to approximately 8% for people aged 85 years and older. Based on the projected ageing of the population, these numbers will triple by the year 2050 resulting in an increase of nearly 80% in total societal costs per adult. [2]

### DIAGNOSIS OF AD

Late-onset AD typically is defined by onset of symptoms after age 60 and evolves slowly from mildly impaired memory function to severe cognitive loss, terminating inevitably in

#### Financial & competing interests disclosure

The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

complete incapacity and death. Although in recent years there have been significant advances in biomarkers such as plasma A $\beta$ , CSF A $\beta$  and tau, and amyloid imaging for AD and prediction in cognitive decline[3–5], in particular studies of plasma A $\beta$  have produced contradictory results and to date there are no definitive diagnostic tests or biological markers of the disease. The diagnosis during life is based on a clinical examination. The pathological hallmarks in brain include deposits of extracellular  $\beta$ -amyloid protein (A $\beta$ ) in diffuse plaques and plaques containing elements of degenerating neurons (“neuritic plaques”). Intracellular changes include deposits of abnormally hyperphosphorylated tau protein, a microtubule assembly protein, in the form of neurofibrillary tangles. In addition, activation of microglia and loss of neurons and synapses is widespread.

## DISEASE MECHANISMS IMPLICATED BY GENOMIC STUDIES

**Linkage Studies**—Early genetic linkage studies of numerous large pedigrees with early-onset AD (onset age: 30–50 years) led to the discovery of autosomal dominant mutations in the amyloid precursor protein (*APP*), presenilin 1 (*PSEN1*), and presenilin 2 (*PSEN2*) genes. [6–8] These studies suggested a common pathogenic mechanism involving enhanced generation and aggregation of amyloid  $\beta$  protein (A $\beta$ ) (“amyloid cascade hypothesis”). According to this hypothesis,  $\beta$ -secretase (BACE) cleaves APP near the N terminus of the A $\beta$  peptide; then, the membrane-bound C-terminal APP fragment is cleaved by  $\gamma$ -secretase leading to accumulation of A $\beta$ 40 and A $\beta$ 42.[9]

**APP:** APP is located at chromosome 21q21 and encodes a ubiquitously expressed type 1 transmembrane protein. The majority of APP is cleaved within the A $\beta$  domain by  $\alpha$ - and  $\gamma$ -secretases resulting in sAPP $\alpha$  and a C-terminal fragment (CTF), which are both non-toxic[10]. Alternatively, APP can undergo consecutive proteolytic cleavage by  $\beta$ - and  $\gamma$ -secretases generating amyloidogenic A $\beta$ 40 and 42 peptides, sAPP $\beta$  and  $\beta$ -CTF.

Dominant mutations in APP account for ~14% of early-onset cases of AD, with more than 30 mutations described to date (<http://www.molgen.vib-ua.be/ADMutations/>[11]). In addition, two recessive APP mutations (E693D, A673V) can cause early-onset AD and amyloidogenesis[12,13]. The majority of known mutations in APP cluster in the A $\beta$  encoding region. However, early genetic sequencing studies focused on the exon 16 and 17 encoding the A $\beta$  domain, leaving the possibility that there are pathogenic variants in other regions of the gene.

Families carrying APP duplications exhibit classic AD with cerebral amyloid angiopathy (CAA).[12,14–16] In addition, individuals with three copies of chromosome 21 (ie. trisomy 21, Down Syndrome) develop AD neuropathology.[12] In contrast, subjects with partial trisomy of chromosome 21 that does not include the APP gene do not develop clinical or neuropathological AD.[12] The Swedish mutation (KM670/671NL) leading to clinical and neuropathological AD, shows 2–3-fold increased plasma A $\beta$  levels caused by altered  $\beta$ -secretase activity [17]. APP mutations clustering at the C-terminal ending of the A $\beta$  domain alter  $\gamma$ -secretase function, shifting APP processing towards an increase in the highly amyloidogenic A $\beta$ 42 fragment and reduction in the less toxic A $\beta$ 40 fragment. The Dutch APP mutation (E693Q) occurs in the A $\beta$  domain and results in accelerated A $\beta$  aggregation.

[12] Individuals carrying this variant develop hereditary cerebral hemorrhage with amyloidosis characterized by predominant vascular A $\beta$  deposition with diffuse plaques in the parenchymal tissue.[12] The E693Delta (Osaka) mutation identified in Japanese pedigree enhances A $\beta$  oligomerization.[18] The Arctic mutation (E693G) also occurring within the A $\beta$  domain[12] does not modify absolute A $\beta$  levels or the A $\beta$ 42/A $\beta$ 40 ratio but is believed to increase the propensity of the A $\beta$  peptide to aggregate[19]. These findings strongly support the notion that A $\beta$  aggregation is critical to AD pathogenesis in these cases.

**PSEN1 and PSEN2:** PSEN1 and PSEN2, localizing in the endoplasmic reticulum and Golgi apparatus, form together with nicastrin, presenilin enhancer 2 (PEN2) and anterior pharynx-defective-1 (APH-1) the  $\gamma$ -secretase complex. Kinetic studies have demonstrated that familial AD mutations in PSEN1 and PSEN2 can exert their effect by various mechanisms: they can affect  $\gamma$ -secretase function by inhibiting the initial endoproteolytic cleavage releasing the intracellular domain of APP; they can lead to a premature release of intermediary substrates of APP during  $\gamma$ -secretase processing leading to the generation of longer A $\beta$  peptides; and they can exert an effect on the cleavage site leading to preferential cleavage of APP at position 49–50 or 51–50[20]. In PSEN1 located at 14q24.3, 185 dominant pathogenic mutations have been identified, accounting for approximately 80% of early-onset familial AD cases (<http://www.molgen.vib-ua.be/ADMutations/>).[11] One of these mutations, the PSEN1 E280A mutation[21–23] causing early-onset familial Alzheimer's disease (EOFAD) at a mean age of 49 years and showing brain imaging and CSF evidence of A $\beta$  plaque accumulation, was identified in the world's largest known autosomal dominant AD kindred residing in Antioquia, Colombia[21].

In its homolog PSEN2 located at 1q31-q42, 13 dominant pathogenic mutations have been identified accounting for approximately 5% of early-onset AD cases (<http://www.molgen.ua.ac.be/admutations/>).[12] In addition, variants with unclear pathogenicity have been described in both genes. There is evidence that some of these mutations, such as PSEN1 E318G[24] and PSEN2 R62H[25] may be risk factors for AD. Finally, also in late-onset AD cases with a strong family history of disease dominantly inherited mutations in PSEN1 and APP have been identified. These families may carry additional genetic variants that delay age at onset of the normally fully penetrant disease mutation.

**ADAM10:** Further support for the hypothesis that alteration of APP processing and A $\beta$  generation is sufficient to cause AD comes from the identification of rare coding variants in ADAM10 in seven late-onset AD families.[26] ADAM10, located at 15q22, encodes the major  $\alpha$ -secretase involved in cleavage of the APP ectodomain [26]. The ADAM10 risk variants R181G and Q170H increase A $\beta$  levels *in vitro*[26] and disrupt  $\alpha$ -secretase activity and shift APP processing toward amyloidogenic cleavage in Tg2576 mice, resulting in increased plaque load[27].

**Role of rare and common variants in late-onset AD**—For several decades, the main hypothesis advocated for complex diseases such as the late-onset form of AD was the “common disease-common variant hypothesis” suggesting that the genetic factors underlying common diseases such as late-onset AD will be alleles that are themselves quite common in the population at large.[28] In line with this notion, over the past several years,

the most common strategy for finding novel gene candidates for late-onset AD has been the genome-wide association study (GWAS), in which as many as several million genetic markers (single nucleotide polymorphisms, SNPs) are simultaneously tested for genetic association with disease risk and/or disease endophenotypes such as age-of-onset, biomarkers, brain imaging measures or neuropathological endpoints. Overall, these studies have identified loci accounting for only part of the heritability of most complex diseases. Although some of this ‘missing heritability’ may be ascribed to a large number of common variants with weak effect that are only detectable in larger studies, it is now clear that there is a substantial contribution from rare variants with large effect that are not readily identifiable by SNP-based methods.[29,30] To address this issue, recent and ongoing work has focused on targeted resequencing of known risk loci and whole genome (WGS) and whole exome (WES) sequencing to reveal rare variants explaining part of the “missing heritability”.

**Apolipoprotein E (APOE) region**—For more than a decade, only one genetic risk factor, the *APOE* $\epsilon$ 4 allele, located on chromosome 19q13, was an unequivocally established “susceptibility” gene in non-Hispanic whites of European ancestry. APOE is a lipid-binding protein and is expressed in humans as three common isoforms coded for by three alleles, APOE $\epsilon$ 2,  $\epsilon$ 3, and  $\epsilon$ 4. A single *APOE*- $\epsilon$ 4 allele is associated with a 2- to 3-fold increased risk, having two copies is associated with a five-fold or more increase.[31] In addition, each inherited APOE $\epsilon$ 4 allele lowers the age-at-onset by 6–7 years.[32–39] APOE $\epsilon$ 4 is also associated with lower cognitive performance, in particular the memory domain, is associated with mild cognitive impairment (MCI) [40–43] and with progression from MCI to dementia [40–50]. While the population attributable risk for APOE $\epsilon$ 4 is estimated at 20–50%, [51] the presence of  $\epsilon$ 4 is neither necessary nor sufficient for developing the disease [52]. In ethnic groups other than non-Hispanic whites, the association between *APOE* and LOAD is largely inconsistent across studies.

**Findings from candidate gene and GWA studies**—Due to a paucity of data in other ethnic groups, most genetic association studies have restricted their efforts to non-Hispanic white populations. In addition, there are differences in linkage disequilibrium (LD) and allele frequencies between ethnic groups, which can lead to genetic background noise and the likelihood of false-positive findings due to confounding in combined analyses. Consequently, the largest GWAS to date which included up to 75,000 subjects were performed in individuals of European ancestry. These GWAS studies identified *CRI*, *BINI*, *CD2AP*, *EPHA1*, *CLU*, *MS4A6A*, *PICALM*, *ABCA7*, *HLA-DRB5/HLA-DRB1*, *PTK2B*, *SORL1*, *SLC24A4/RIN3*, *INPP5D*, *MEF2C*, *NME8*, *ZCWPW1*, *CELF1*, *FERMT2*, *CASS4*, *CD33* and *EPHA1* as AD susceptibility loci.[53–58] The majority of these genes cluster into three pathways: inflammation and immune response, lipid metabolism and endocytosis/ intracellular trafficking. The *SORL1* (sortilin-related receptor, L(DLR class) 1) gene had previously been demonstrated to modulate intracellular trafficking and processing of APP in a candidate gene approach.[59,60] *CLU*, also known as apolipoprotein J (ApoJ), is a lipoprotein highly expressed in both the periphery and the brain.[61] Like ApoE, it is involved in lipid transport.[62] *CLU* is also hypothesized to act as an extracellular chaperone that influences A $\beta$ -aggregation and receptor-mediated A $\beta$  clearance by

endocytosis.[61] *BINI* (amphiphysin II) is a member of the Bin1/amphiphysin/RVS167 (BAR) family of genes that are involved in diverse cellular processes, including actin dynamics, membrane trafficking and clathrin-mediated endocytosis[63] which affect APP processing and A $\beta$  production or A $\beta$  clearance from brain. *PICALM* is also involved in clathrin-mediated endocytosis and recruits clathrin and adaptor protein complex 2 to sites of vesicle assembly[64]. *CD33* encodes a type I transmembrane protein belonging to the sialic acid-binding immunoglobulin-like lectins, mediating the cell-cell interaction and inhibiting normal functions of immune cells. In the periphery, *CD33* is expressed on myeloid cells and monocytes. In the brain, *CD33* is mainly expressed on microglial cells and is involved in microglia-mediated clearance of A $\beta$ . *CR1* is part of the complement system and a cell-surface receptor that is involved in clearing immune-complexes containing C3b and C4b. C3b can bind A $\beta$  oligomers; consequently it is possible *CR1* is involved in A $\beta$  clearance. *CR1* may also play a role in AD through neuroinflammation.[65] Of note, in this process *CLU* may play a role as an inhibitor[66]. The *MS4A4A/MS4A4E/MS4A6E* locus is on chromosome 11 and part of a cluster of 15 *MS4A* genes. Like *CD33*, *MS4A4A* is expressed on myeloid cells and monocytes and likely has an immune-related function. *EPHA1* belongs to the ephrin receptor subfamily of the protein-tyrosine kinase family. Members of this family of cell surface receptors interact with ephrin ligands on adjacent cells to modulate cell adhesion, migration, axon guidance, synapse formation and plasticity. Like other ephrin receptors, *EPHA1* regulates cell morphology and motility[67]. In humans, *EPHA1* is expressed by intestinal epithelium, colon but also CD4-positive T lymphocytes[68] and monocytes[69]. This may suggest that, like *CD33*, *CR1*, and *MS4A4/MS4A6E*, the role of the *EPHA1* gene product in AD may be mediated through the immune system. *CD2AP* encodes a scaffolding protein binding directly to actin, nephrin and other proteins involved in cytoskeletal organization[70]. It is implicated in dynamic actin remodeling and membrane trafficking that occurs during receptor endocytosis and cytokinesis. In the immune system, *CD2AP* is required for synapse formation.[71] *ABCA7* is a member of the superfamily of ATP-binding cassette (ABC) transporters. ABC proteins transport various molecules across extra- and intra-cellular membranes. *ABCA7* binds APOA-I and functions in apolipoprotein-mediated phospholipid and cholesterol efflux from cells.[72] In addition, *ABCA7* affects the transport of other important proteins, including amyloid precursor protein, [72] through the cell membrane and is involved in host defense through effects on phagocytosis by macrophages of apoptotic cells.[73] The largest GWAS performed in African Americans confirmed this gene as a susceptibility locus.[74] A recent study indicates that the common variants identified in these GWAS genes explain 33% of the total phenotypic variance out of which *APOE* alone explains 6% and other known markers 2%, leaving more than 25% of phenotypic variance to be identified[75].

## RECENT SEQUENCING STUDIES

**TREM2 and TREML2**—Two whole-exome and whole-genome sequencing studies performed in persons of European ancestry identified simultaneously a rare disease-associated variant (rs75932628, R47H) increasing the risk 3–4-fold in the gene encoding triggering receptor expressed on myeloid cells 2 (*TREM2*).[76,77] A study in African Americans confirmed this association.[78] *TREM2* is a receptor of the innate immune system expressed on microglia, macrophages, dendritic cells and osteoclasts, and a member

of the immunoglobulin superfamily. [79] Endogenous ligands of this receptor are unknown but when triggered, it signals through the transmembrane adapter protein TYROBP/DAP12 to activate phagocytosis of pathogens and cellular debris. In addition, TREM2 suppresses expression and secretion of inflammatory cytokines in macrophages and microglia. Autosomal recessive mutations in TREM2 cause Nasu-Hakola disease, a rare genetic disorder characterized by bone cysts and progressive early-onset dementia fatal by mid-life. [80] In addition to R47H, several additional rare variants in TREM2 were observed more frequently in cases than controls, [76,81], and a common protective variant (p.S144G (rs3747742)) has been identified in TREML2[82] suggesting that there may be multiple rare or common disease-associated variants in this gene family. There is also evidence that TREM2 R47H could be associated with Parkinson's disease, frontotemporal dementia, and amyotrophic lateral sclerosis[83–85]. The identification of coding variants in TREM2 and TREML2 that increase risk for AD supports the role of the immune response and inflammation in AD pathogenesis.

**PLD3**—Whole-exome sequencing (WES) in 14 large families densely affected by late-onset AD combined with consecutive analyses in several large case-control data sets identified a rare disease-associated variant in PLD3 (phospholipase D3; Val232Met).[75] Subsequent gene-based analyses of PLD3 sequence data in 4,387 cases and controls of European descent and 302 African American cases and controls, suggested that in both ethnic groups numerous variants in this gene increase risk for AD.[75] PLD3 is highly expressed in brain regions affected by the AD process including the cortex and hippocampus and is significantly lower expressed in neurons from AD brains compared to control brains. Overexpression of PLD3 leads to a significant decrease in intracellular APP and extracellular A $\beta$ 42 and A $\beta$ 40, and knockdown of PLD3 leads to a significant increase in extracellular A $\beta$ 42 and A $\beta$ 40.[75] For both TREM2/TREML2 and PLD3 as well as most genes identified by GWAS, the specific mechanisms by which they affect AD pathogenesis need to be disentangled.

## USE OF GENOMIC INFORMATION FOR DISEASE DIAGNOSIS AND PROGNOSIS

In addition to pointing to mechanisms involved in the disease pathogenesis, identification of genetic risk factors could theoretically improve patient care by incorporation into a diagnostic or predictive test for AD allowing more targeted medical intervention (ie. 'genetic profiling'). While the level of discriminative accuracy considered acceptable is clearly dependent on the invasive nature of the treatment, to date, the feasibility of genetic risk profiling for AD diagnosis and prognosis is limited because the currently identified genes only explain a small proportion of the heritability of AD.[12,86] This limited diagnostic utility for AD diagnosis and prognosis is in line with similar observations in other common complex diseases and traits. A 54-locus genetic profile for the highly heritable trait height predicted only 5.6% of variation compared with 40% achieved by traditional predictions based on parental height[87]. In a large metaanalysis of 22,720 initially stroke-free subjects, a 324 SNP risk score for stroke led only to a marginal improvement in risk prediction compared with the classical epidemiological risk factors for stroke, and genetic risk profiling alone was inferior in predictive power to clinical risk profiling alone.[88] Similar observations have been made for diabetes[89,90] and hypertension[91]. A



simulation study of genetic profiles for coronary heart disease suggests that 50 variants with ORs of 1.2 and genotype frequencies of 50% are needed to reach a discriminative accuracy of ~70% [92]. At allele frequencies of 30% this number doubles to 100 variants.[92] Also, because of the strength of association between *APOE* and AD, for prediction of AD a weighted or log-odds risk score seems more appropriate than an unweighted approach [93]. Ideally, genetic profiling would also need to be complemented with information on environmental risk exposures.

As opposed to genetic profiling using only the established genome-wide significant risk variants, a genomic profiling approach includes all nominally associated SNPs in a genome-wide association study. To date, this method still has limited discriminative accuracy for complex diseases with no known strong genetic risk determinants, reaching only discriminative values of 55–60% for diseases such as type 2 diabetes, bipolar disorder or coronary heart disease [93]. It is expected that the current large-scale collaborative studies including GWAS, whole-genome and whole-exome sequencing studies, whole-genome copy number variant analysis, epistasis and pathway analyses as well as analyses in ethnic groups other than non-Hispanic whites will identify additional rare and common disease-associated variants and improve the predictive power of genetic or genomic profiling.

## USE OF GENETIC INFORMATION FOR TREATMENT

Over the past two decades, drugs and potential druggable targets have not been successfully translated from animal models into effective therapies for humans. The failure of the conducted Phase 3 clinical trials targeting amyloid beta may be to some extent explained by their study design [94,95]. Most of these trials were based on subjects with mild to moderate dementia and a clinical diagnosis of late-onset AD, not taking into account the degree of brain amyloid load. However, as expected from a heterogeneous disease, recent studies have shown that a significant subset of the subjects in these trials were amyloid negative on neuroimaging; thus, they were *a priori* unlikely to respond to anti-amyloid treatment.[96] Also, A $\beta$  deposition predominantly occurs in the preclinical phase of the disease, and drug-related reversal of A $\beta$  deposition may have no impact on disease progression after clinical symptoms have manifested and synapse loss and neurodegeneration have taken place.

Use of a genetic profile can advance drug development by identifying participants eligible for, most likely to benefit from or least likely to experience adverse effects of a targeted therapeutic approach. In line with this notion, two clinical trials launched in 2013 that are targeting A $\beta$ , make use of genetic information focusing on dominantly inherited AD cases in the preclinical stage of disease who are known to develop AD at a certain age and carry mutations causing disease by increasing A $\beta$  production (ie. *APP*, *PSEN1*, *PSEN2* mutations). The Dominantly Inherited Alzheimer Network (DIAN) study[97,98] is testing Gantenerumab and Solanezumab in families carrying various *APP*, *PSEN1* and *PSEN2* mutations. The Alzheimer's disease Prevention Initiative (API)[99,100] is testing Crenezumab in presymptomatic individuals from the extended Colombian kindred carrying the *PSEN1* E280A mutation. A third trial, the A4 study[101] by the Alzheimer's Disease Cooperative Study (ADCS), is testing Solanezumab on asymptomatic elderly aged 65–85 years whose AD mutation carrier status is unknown but who have a high A $\beta$  burden on brain

imaging. Initial outcomes in all these trials will be a change in plasma, CSF and imaging biomarkers of AD, follow-up studies will assess several clinical and cognitive outcomes.[95]

Plasma biomarkers of AD include A $\beta$ 40 and A $\beta$ 42[102] whose brain level is under physiological conditions balanced by the peripheral production by platelets and production and deposition of A $\beta$  in the brain. In non-demented persons, plasma A $\beta$  concentrations reflect brain A $\beta$  levels. In familial AD[103] and Down syndrome with *APP* triplication[104], total plasma A $\beta$  levels and A $\beta$ <sub>1-42</sub> levels are increased. The usefulness of plasma A $\beta$  as a risk biomarker for sporadic AD remains controversial [105,106] but there is evidence that elevated plasma A $\beta$ <sub>1-42</sub> is an antecedent risk factor for sporadic AD, while decreasing levels or a decline in the A $\beta$ <sub>1-42</sub>/A $\beta$ <sub>1-40</sub> ratio indicate disease onset.

CSF biomarkers of AD include levels of A $\beta$ <sub>1-42</sub>, total tau (t-tau) and p-tau.[107] In MCI or AD CSF levels of A $\beta$ <sub>1-42</sub> are decreased while t-tau or p-tau are increased compared to non-demented subjects. The combined assessment of A $\beta$ <sub>1-37</sub>, A $\beta$ <sub>1-38</sub>, A $\beta$ <sub>1-39</sub>, A $\beta$ <sub>1-40</sub> and A $\beta$ <sub>1-42</sub> may further increase sensitivity and specificity in predicting progression from early cognitive impairment to AD[109].

Typical changes on structural MRI include atrophy in the medial temporal lobe in particular in the hippocampus and the amygdala.[110] In addition, white matter changes may be present. Atrophy in the hippocampus and entorhinal cortex is associated with a decline in memory function, progression of memory impairment[111] and an increased risk of AD[110,112]. On functional MRI (fMRI) AD is characterized by a decreased BOLD signal in the medial temporal lobe, parietal lobe and hippocampus during a cognitive task.[113] On positron emission tomography (PET) the amyloid specific imaging probe Pittsburgh compound B (PIB) binds selectively to cortical and striatal A $\beta$  plaques, shows a strong positive correlation with AD diagnosis, fibrillary amyloid plaques at autopsy [114] and is inversely correlated with CSF A $\beta$ 42 levels in the presence of clinical AD[115]. Florbetaben (<sup>18</sup>F-BAY94-9172) and Flortetapir (<sup>18</sup>F AV-45) are amyloid imaging agents with similar binding profiles but longer half-life than PIB which can also differentiate AD from controls and other dementias [116,117] On <sup>18</sup>F-fluorodeoxyglucose (FDG)-PET imaging cerebral metabolism is decreased in AD, in particular in the parietal lobe.[118]

Newly identified risk genes can also advance drug development for AD by identifying novel therapeutic targets such as the complement, chaperone or cholesterol pathways. Whether these strategies are worth pursuing in AD not only depends on the potential of the compounds to cross the blood-brain barrier and the underlying mechanisms through which these genes are involved in AD. Sequencing studies are expected to uncover functional variants shedding light on these mechanisms by their nature (gain or loss of function) and/or location in specific functional domains, splice sites or regulatory regions.

## EXPERT COMMENTARY

GWAS have identified more than 20 genomic susceptibility loci modifying AD risk. Common variants explain ~33% of the total phenotypic variance leaving a significant part of the phenotypic variance to be identified [75]. Ongoing studies using even larger sample sizes will likely identify additional loci with smaller effect sizes or allele frequencies. In





## Acknowledgments

C Reitz was supported by a Paul B. Beeson Career Development Award (K23AG034550).

## References

1. Hurd MD, Martorell P, Delavande A, Mullen KJ, Langa KM. Monetary costs of dementia in the United States. *N Engl J Med*. 2013; 368(14):1326–1334. [PubMed: 23550670]
2. 2010 Alzheimer's disease facts and figures. *Alzheimers Dement*. 2010; 6(2):158–194. [PubMed: 20298981]
3. Roe CM, Fagan AM, Grant EA, Holtzman DM, Morris JC. CSF biomarkers of Alzheimer disease: “noncognitive” outcomes. *Neurology*. 2013; 81(23):2028–2031. [PubMed: 24212387]
4. Rowe CC, Bourgeat P, Ellis KA, et al. Predicting Alzheimer disease with beta-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing. *Ann Neurol*. 2013; 74(6):905–913. [PubMed: 24448836]
5. Laske C. Blood-based biomarkers in Alzheimer disease: where are we now and where have we to go? *JAMA Neurol*. 2013; 70(1):133. [PubMed: 23318524]
6. Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. *Nature*. 1991; 349(6311):704–706. [PubMed: 1671712]
7. Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. *Science*. 1995; 269(5226):973–977. [PubMed: 7638622]
8. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. *Nature*. 1995; 375(6534):754–760. [PubMed: 7596406]
9. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. *Science*. 1992; 256(5054):184–185. [PubMed: 1566067]
10. Thinakaran G, Koo EH. Amyloid precursor protein trafficking, processing, and function. *J Biol Chem*. 2008; 283(44):29615–29619. [PubMed: 18650430]
11. Cruts M, Theuns J, Van Broeckhoven C. Locus-specific mutation databases for neurodegenerative brain diseases. *Hum Mutat*. 2012; 33(9):1340–1344. [PubMed: 22581678]
12. Guerreiro RJ, Gustafson DR, Hardy J. The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE. *Neurobiol Aging*. 2012; 33(3):437–456. [PubMed: 20594621]
13. Di Fede G, Catania M, Morbin M, et al. A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. *Science*. 2009; 323(5920):1473–1477. [PubMed: 19286555]
14. Remes AM, Finnila S, Mononen H, et al. Hereditary dementia with intracerebral hemorrhages and cerebral amyloid angiopathy. *Neurology*. 2004; 63(2):234–240. [PubMed: 15277614]
15. Rovelet-Lecrux A, Frebourg T, Tuominen H, Majamaa K, Campion D, Remes AM. APP locus duplication in a Finnish family with dementia and intracerebral haemorrhage. *J Neurol Neurosurg Psychiatry*. 2007; 78(10):1158–1159. [PubMed: 17442758]
16. Sleegers K, Brouwers N, Gijselinck I, et al. APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. *Brain*. 2006; 129(Pt 11):2977–2983. [PubMed: 16921174]
17. Mullan M, Crawford F, Axelman K, et al. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. *Nat Genet*. 1992; 1(5):345–347. [PubMed: 1302033]
18. Tomiyama T, Nagata T, Shimada H, et al. A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. *Ann Neurol*. 2008; 63(3):377–387. [PubMed: 18300294]
19. Nilsberth C, Westlind-Danielsson A, Eckman CB, et al. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. *Nat Neurosci*. 2001; 4(9):887–893. [PubMed: 11528419]
20. Chavez-Gutierrez L, Bammens L, Benilova I, et al. The mechanism of gamma-Secretase dysfunction in familial Alzheimer disease. *EMBO J*. 2012; 31(10):2261–2274. [PubMed: 22505025]

21. Lalli MA, Cox HC, Arcila ML, et al. Origin of the PSEN1 E280A mutation causing early-onset Alzheimer's disease. *Alzheimers Dement*. 2014; 10(5 Suppl):S277–S283. e210. [PubMed: 24239249]
22. Lopera F, Ardilla A, Martinez A, et al. Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. *JAMA*. 1997; 277(10):793–799. [PubMed: 9052708]
23. Reiman EM, Quiroz YT, Fleisher AS, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. *Lancet Neurol*. 2012; 11(12):1048–1056. [PubMed: 23137948]
24. Benitez BA, Karch CM, Cai Y, et al. The PSEN1, p.E318G variant increases the risk of Alzheimer's disease in APOE-epsilon4 carriers. *PLoS Genet*. 2013; 9(8):e1003685. [PubMed: 23990795]
25. Cruchaga C, Haller G, Chakraverty S, et al. Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families. *PLoS One*. 2012; 7(2):e31039. [PubMed: 22312439]
26. Kim M, Suh J, Romano D, et al. Potential late-onset Alzheimer's disease-associated mutations in the ADAM10 gene attenuate {alpha}-secretase activity. *Hum Mol Genet*. 2009; 18(20):3987–3996. [PubMed: 19608551]
27. Suh J, Choi SH, Romano DM, et al. ADAM10 missense mutations potentiate beta-amyloid accumulation by impairing prodomain chaperone function. *Neuron*. 2013; 80(2):385–401. [PubMed: 24055016]
28. Lander ES. The new genomics: global views of biology. *Science*. 1996; 274(5287):536–539. [PubMed: 8928008]
29. Pritchard JK. Are rare variants responsible for susceptibility to complex diseases? *Am J Hum Genet*. 2001; 69(1):124–137. [PubMed: 11404818]
30. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. *Nature*. 2009; 461(7265):747–753. [PubMed: 19812666]
31. Kuusisto J, Koivisto K, Kervinen K, et al. Association of apolipoprotein E phenotypes with late onset Alzheimer's disease: population based study. *BMJ*. 1994; 309(6955):636–638. [PubMed: 8086986]
32. Breitner JC, Wyse BW, Anthony JC, et al. APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study. *Neurology*. 1999; 53(2):321–331. [PubMed: 10430421]
33. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science*. 1993; 261(5123):921–923. [PubMed: 8346443]
34. Gomez-Isla T, West HL, Rebeck GW, et al. Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. *Ann Neurol*. 1996; 39(1):62–70. [PubMed: 8572669]
35. Holmes C, Levy R, McLoughlin DM, Powell JF, Lovestone S. Apolipoprotein E: non-cognitive symptoms and cognitive decline in late onset Alzheimer's disease. *J Neurol Neurosurg Psychiatry*. 1996; 61(6):580–583. [PubMed: 8971103]
36. Kurz A, Altland K, Lautenschlager N, et al. Apolipoprotein E type 4 allele and Alzheimer's disease: effect on age at onset and relative risk in different age groups. *J Neurol*. 1996; 243(6):452–456. [PubMed: 8803817]
37. Murman DL, Foster NL, Kilgore SP, McDonagh CA, Fink JK. Apolipoprotein E and Alzheimer's disease: strength of association is related to age at onset. *Dementia*. 1996; 7(5):251–255. [PubMed: 8872415]
38. Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. *Lancet*. 1993; 342(8873):697–699. [PubMed: 8103819]
39. Roses AD. Alzheimer's disease: the genetics of risk. *Hosp Pract (Minneap)*. 1997; 32(7):51–55. 58–63, 67–59.
40. Barabash A, Marcos A, Ancin I, et al. APOE, ACT and CHRNA7 genes in the conversion from amnesic mild cognitive impairment to Alzheimer's disease. *Neurobiology of aging*. 2007

41. Petersen RC, Smith GE, Ivnik RJ, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. *Jama*. 1995; 273(16):1274–1278. [PubMed: 7646655]
42. Sasaki M, Kodama C, Hidaka S, et al. Prevalence of four subtypes of mild cognitive impairment and APOE in a Japanese community. *International journal of geriatric psychiatry*. 2009
43. Tyas SL, Salazar JC, Snowdon DA, et al. Transitions to mild cognitive impairments, dementia, and death: findings from the Nun Study. *American journal of epidemiology*. 2007; 165(11):1231–1238. [PubMed: 17431012]
44. Blom ES, Giedraitis V, Zetterberg H, et al. Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype. *Dementia and geriatric cognitive disorders*. 2009; 27(5):458–464. [PubMed: 19420940]
45. Devanand DP, Pelton GH, Zamora D, et al. Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment. *Archives of neurology*. 2005; 62(6):975–980. [PubMed: 15956169]
46. Hamalainen A, Grau-Olivares M, Tervo S, et al. Apolipoprotein E epsilon 4 allele is associated with increased atrophy in progressive mild cognitive impairment: a voxel-based morphometric study. *Neuro-degenerative diseases*. 2008; 5(3–4):186–189. [PubMed: 18322386]
47. Hsiung GY, Sadovnick AD, Feldman H. Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging. *Cmaj*. 2004; 171(8):863–867. [PubMed: 15477624]
48. Jack CR Jr, Petersen RC, Xu YC, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. *Neurology*. 1999; 52(7):1397–1403. [PubMed: 10227624]
49. Ramakers IH, Visser PJ, Aalten P, et al. The association between APOE genotype and memory dysfunction in subjects with mild cognitive impairment is related to age and Alzheimer pathology. *Dementia and geriatric cognitive disorders*. 2008; 26(2):101–108. [PubMed: 18617739]
50. Tierney MC, Szalai JP, Snow WG, et al. A prospective study of the clinical utility of ApoE genotype in the prediction of outcome in patients with memory impairment. *Neurology*. 1996; 46(1):149–154. [PubMed: 8559365]
51. Slioter AJ, Cruts M, Kalmijn S, et al. Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. *Archives of neurology*. 1998; 55(7):964–968. [PubMed: 9678314]
52. Myers RH, Schaefer EJ, Wilson PW, et al. Apolipoprotein E epsilon4 association with dementia in a population-based study: The Framingham study. *Neurology*. 1996; 46(3):673–677. [PubMed: 8618665]
53. Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. *Nat Genet*. 2009; 41(10):1088–1093. [PubMed: 19734902]
54. Naj AC, Jun G, Beecham GW, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. *Nat Genet*. 2011; 43(5):436–441. [PubMed: 21460841]
55. Seshadri S, Fitzpatrick AL, Ikram MA, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. *JAMA*. 2010; 303(18):1832–1840. [PubMed: 20460622]
56. Lambert JC, Heath S, Even G, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. *Nat Genet*. 2009; 41(10):1094–1099. [PubMed: 19734903]
57. Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nat Genet*. 2013
58. Hollingworth P, Harold D, Sims R, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. *Nat Genet*. 2011; 43(5):429–435. [PubMed: 21460840]
59. Rogava E, Meng Y, Lee JH, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. *Nat Genet*. 2007; 39(2):168–177. [PubMed: 17220890]

60. Reitz C, Cheng R, Rogaeva E, et al. Meta-analysis of the association between variants in SORL1 and Alzheimer's disease. *Archives of neurology*. 2010 In press.
61. Nuutinen T, Suuronen T, Kauppinen A, Salminen A. Clusterin: a forgotten player in Alzheimer's disease. *Brain Res Rev*. 2009; 61(2):89–104. [PubMed: 19651157]
62. Wollmer MA, Slegers K, Ingelsson M, et al. Association study of cholesterol-related genes in Alzheimer's disease. *Neurogenetics*. 2007; 8(3):179–188. [PubMed: 17387528]
63. Pant S, Sharma M, Patel K, Caplan S, Carr CM, Grant BD. AMPH-1/Amphiphysin/Bin1 functions with RME-1/Ehd1 in endocytic recycling. *Nat Cell Biol*. 2009; 11(12):1399–1410. [PubMed: 19915558]
64. Tebar F, Bohlander SK, Sorkin A. Clathrin assembly lymphoid myeloid leukemia (CALM) protein: localization in endocytic-coated pits, interactions with clathrin, and the impact of overexpression on clathrin-mediated traffic. *Mol Biol Cell*. 1999; 10(8):2687–2702. [PubMed: 10436022]
65. Crehan H, Holton P, Wray S, Pocock J, Guerreiro R, Hardy J. Complement receptor 1 (CR1) and Alzheimer's disease. *Immunobiology*. 2012; 217(2):244–250. [PubMed: 21840620]
66. McGeer PL, Rogers J. Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. *Neurology*. 1992; 42(2):447–449. [PubMed: 1736183]
67. Yamazaki T, Masuda J, Omori T, Usui R, Akiyama H, Maru Y. EphA1 interacts with integrin-linked kinase and regulates cell morphology and motility. *J Cell Sci*. 2009; 122(Pt 2):243–255. [PubMed: 19118217]
68. Holen HL, Nustad K, Aasheim HC. Activation of EphA receptors on CD4+CD45RO+ memory cells stimulates migration. *J Leukoc Biol*. 2010; 87(6):1059–1068. [PubMed: 20160140]
69. Sakamoto A, Sugamoto Y, Tokunaga Y, et al. Expression profiling of the ephrin (EFN) and Eph receptor (EPH) family of genes in atherosclerosis-related human cells. *J Int Med Res*. 2011; 39(2):522–527. [PubMed: 21672356]
70. Lehtonen S, Zhao F, Lehtonen E. CD2-associated protein directly interacts with the actin cytoskeleton. *Am J Physiol Renal Physiol*. 2002; 283(4):F734–743. [PubMed: 12217865]
71. Dustin ML, Olszowy MW, Holdorf AD, et al. A novel adaptor protein orchestrates receptor patterning and cytoskeletal polarity in T-cell contacts. *Cell*. 1998; 94(5):667–677. [PubMed: 9741631]
72. Chan SL, Kim WS, Kwok JB, et al. ATP-binding cassette transporter A7 regulates processing of amyloid precursor protein in vitro. *J Neurochem*. 2008; 106(2):793–804. [PubMed: 18429932]
73. Tanaka N, Abe-Dohmae S, Iwamoto N, Yokoyama S. Roles of ATP-binding cassette transporter A7 in cholesterol homeostasis and host defense system. *J Atheroscler Thromb*. 2011; 18(4):274–281. [PubMed: 21173549]
74. Reitz C, Jun G, Naj A, et al. Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E 4, and the risk of late-onset Alzheimer disease in African Americans. *JAMA*. 2013; 309(14):1483–1492. [PubMed: 23571587]
75. Cruchaga C, Karch CM, Jin SC, et al. Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease. *Nature*. 2014; 505(7484):550–554. [PubMed: 24336208]
76. Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in Alzheimer's disease. *N Engl J Med*. 2013; 368(2):117–127. [PubMed: 23150934]
77. Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. *N Engl J Med*. 2013; 368(2):107–116. [PubMed: 23150908]
78. Reitz C, Mayeux R. TREM2 and neurodegenerative disease. *N Engl J Med*. 2013; 369(16):1564–1565. [PubMed: 24131184]
79. Colonna M. TREMs in the immune system and beyond. *Nat Rev Immunol*. 2003; 3(6):445–453. [PubMed: 12776204]
80. Paloneva J, Mandelin J, Kiialainen A, et al. DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features. *J Exp Med*. 2003; 198(4):669–675. [PubMed: 12925681]
81. Cuyvers E, Bettens K, Philtjens S, et al. Investigating the role of rare heterozygous TREM2 variants in Alzheimer's disease and frontotemporal dementia. *Neurobiol Aging*. 2014; 35(3):726–e711–729. [PubMed: 24119542]



82. Benitez BA, Jin SC, Guerreiro R, et al. Missense variant in TREML2 protects against Alzheimer's disease. *Neurobiol Aging*. 2014; 35(6):1510, e1519–1526. [PubMed: 24439484]
83. Guerreiro R, Bilgic B, Guven G, et al. Novel compound heterozygous mutation in TREM2 found in a Turkish frontotemporal dementia-like family. *Neurobiol Aging*. 2013; 34(12):2890, e2891–2895. [PubMed: 23870839]
84. Lattante S, Le Ber I, Camuzat A, et al. TREM2 mutations are rare in a French cohort of patients with frontotemporal dementia. *Neurobiol Aging*. 2013; 34(10):2443 e2441–2442. [PubMed: 23759145]
85. Rayaprolu S, Mullen B, Baker M, et al. TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease. *Mol Neurodegener*. 2013; 8:19. [PubMed: 23800361]
86. Maher B. Personal genomes: The case of the missing heritability. *Nature*. 2008; 456(7218):18–21. [PubMed: 18987709]
87. Aulchenko YS, Struchalin MV, Belonogova NM, et al. Predicting human height by Victorian and genomic methods. *Eur J Hum Genet*. 2009; 17(8):1070–1075. [PubMed: 19223933]
88. Ibrahim-Verbaas CA, Fornage M, Bis JC, et al. Predicting stroke through genetic risk functions: the CHARGE Risk Score Project. *Stroke*. 2014; 45(2):403–412. [PubMed: 24436238]
89. Muhlenbruch K, Jeppesen C, Joost HG, Boeing H, Schulze MB. The value of genetic information for diabetes risk prediction - differences according to sex, age, family history and obesity. *PLoS One*. 2013; 8(5):e64307. [PubMed: 23700469]
90. Anand SS, Meyre D, Pare G, et al. Genetic information and the prediction of incident type 2 diabetes in a high-risk multiethnic population: the EpiDREAM genetic study. *Diabetes Care*. 2013; 36(9):2836–2842. [PubMed: 23603917]
91. Fava C, Sjogren M, Montagnana M, et al. Prediction of blood pressure changes over time and incidence of hypertension by a genetic risk score in Swedes. *Hypertension*. 2013; 61(2):319–326. [PubMed: 23232644]
92. van der Net JB, Janssens AC, Sijbrands EJ, Steyerberg EW. Value of genetic profiling for the prediction of coronary heart disease. *Am Heart J*. 2009; 158(1):105–110. [PubMed: 19540399]
93. Evans DM, Visscher PM, Wray NR. Harnessing the information contained within genome-wide association studies to improve individual prediction of complex disease risk. *Hum Mol Genet*. 2009; 18(18):3525–3531. [PubMed: 19553258]
94. Bateman RJ, Aisen PS, De Strooper B, et al. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. *Alzheimers Res Ther*. 2011; 3(1):1. [PubMed: 21211070]
95. Moulder KL, Snider BJ, Mills SL, et al. Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. *Alzheimers Res Ther*. 2013; 5(5):48. [PubMed: 24131566]
96. Vellas B, Carrillo MC, Sampaio C, et al. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. *Alzheimers Dement*. 2013; 9(4):438–444. [PubMed: 23809364]
97. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. *N Engl J Med*. 2012; 367(9):795–804. [PubMed: 22784036]
98. Morris JC, Aisen PS, Bateman RJ, et al. Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. *Clin Investig (Lond)*. 2012; 2(10):975–984.
99. Reiman EM, Langbaum JB, Tariot PN. Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. *Biomark Med*. 2010; 4(1):3–14. [PubMed: 20383319]
100. Reiman EM, Langbaum JB, Fleisher AS, et al. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. *J Alzheimers Dis*. 2011; 26(Suppl 3): 321–329. [PubMed: 21971471]
101. Sperling RA, Rentz DM, Johnson KA, et al. The A4 study: stopping AD before symptoms begin? *Sci Transl Med*. 2014; 6(228):228fs213.



102. Hampel H, Lista S, Teipel SJ, et al. Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020. *Biochem Pharmacol.* 2014; 88(4):426–449. [PubMed: 24275164]
103. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. *Nat Med.* 1996; 2(8):864–870. [PubMed: 8705854]
104. Schupf N, Patel B, Silverman W, et al. Elevated plasma amyloid beta-peptide 1–42 and onset of dementia in adults with Down syndrome. *Neurosci Lett.* 2001; 301(3):199–203. [PubMed: 11257432]
105. Mayeux R, Tang MX, Jacobs DM, et al. Plasma amyloid beta-peptide 1–42 and incipient Alzheimer's disease. *Ann Neurol.* 1999; 46(3):412–416. [PubMed: 10482274]
106. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM. Plasma Aβ(1–40) and Aβ(1–42) and the risk of dementia: a prospective case-cohort study. *Lancet Neurol.* 2006; 5(8):655–660. [PubMed: 16857570]
107. Rosen C, Hansson O, Blennow K, Zetterberg H. Fluid biomarkers in Alzheimer's disease - current concepts. *Mol Neurodegener.* 2013; 8:20. [PubMed: 23800368]
108. Ewers M, Zhong Z, Burger K, et al. Increased CSF-BACE 1 activity is associated with ApoE-ε4 genotype in subjects with mild cognitive impairment and Alzheimer's disease. *Brain.* 2008; 131(Pt 5):1252–1258. [PubMed: 18334538]
109. Hoglund K, Hansson O, Buchhave P, et al. Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides. *Neurodegener Dis.* 2008; 5(5):268–276. [PubMed: 18309230]
110. Ewers M, Sperling RA, Klunk WE, Weiner MW, Hampel H. Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. *Trends Neurosci.* 2011; 34(8): 430–442. [PubMed: 21696834]
111. Mungas D, Harvey D, Reed BR, et al. Longitudinal volumetric MRI change and rate of cognitive decline. *Neurology.* 2005; 65(4):565–571. [PubMed: 16116117]
112. Apostolova LG, Dutton RA, Dinov ID, et al. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. *Arch Neurol.* 2006; 63(5):693–699. [PubMed: 16682538]
113. Celone KA, Calhoun VD, Dickerson BC, et al. Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis. *J Neurosci.* 2006; 26(40):10222–10231. [PubMed: 17021177]
114. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. *Ann Neurol.* 2004; 55(3):306–319. [PubMed: 14991808]
115. Jagust WJ, Landau SM, Shaw LM, et al. Relationships between biomarkers in aging and dementia. *Neurology.* 2009; 73(15):1193–1199. [PubMed: 19822868]
116. Barthel H, Gertz HJ, Dresel S, et al. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. *Lancet Neurol.* 2011; 10(5):424–435. [PubMed: 21481640]
117. Camus V, Payoux P, Barre L, et al. Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. *Eur J Nucl Med Mol Imaging.* 2012; 39(4):621–631. [PubMed: 22252372]
118. Landau SM, Harvey D, Madison CM, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. *Neurobiol Aging.* 2011; 32(7):1207–1218. [PubMed: 19660834]

### KEY ISSUES

- Late-onset AD is the most frequent form of dementia affecting 24 million persons worldwide
- The etiology of AD is largely unclear and there is no effective therapy for prevention or treatment
- AD is a pathologically and clinically heterogeneous disease with a strong genetic component to which both common and rare genetic variants contribute
- Mapping of the genes and pathways dysregulated in AD, will allow to improve genomic profiling for AD diagnosis and prognosis, and to develop more targeted and more effective therapeutic measures
- During the last 5 years, genome-wide association studies have mapped more than 20 common disease-associated variants
- Targeted sequencing and whole exome and whole genome sequencing studies have in addition identified rare disease-associated variants in *SORL1*, *PLD3* and *TREM2*
- The identified genetic variants hint to specific pathways involved in AD etiology including inflammation and immune response, lipid metabolism, endocytosis/synaptic function, amyloid processing, tau pathology and synaptic function
- The ongoing large-scale whole-genome and whole-exome sequencing studies are expected to identify numerous additional susceptibility loci within the near future

**Table 1**

Major pathways identified by genomic studies

<b>Pathway</b>	<b>Gene</b>
Amyloid pathway	<i>APOE, SORL1, CLU, CRI, PICALM, BIN1, ABCA7, CASS4, PLD3</i>
Immune system/inflammation	<i>CLU, CRI, EPHA1, ABCA7, MS4A4A/MS4A6E, CD33, CD2AP, HLA-DRB5/DRB1, INPP5D, MEF2C, TREM2/TREML2</i>
Lipid transport and metabolism	<i>APOE, CLU, ABCA7, SORL1</i>
Synaptic cell functioning/endocytosis	<i>CLU, PICALM, BIN1, EPHA1, MS4A4A/MS4A6E, CD33, CD2AP, PTK2B, SORL1, SLC24A4/RIN3, MEF2C</i>
Tau pathology	<i>BIN1, CASS4, FERMT2</i>
Cell migration	<i>PTK2B</i>
Hippocampal synaptic function	<i>MEF2C, PTK2B</i>
Cytoskeletal function and axonal transport	<i>CELF1, NME8, CASS4</i>
microglial and myeloid cell function	<i>INPPD5</i>

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript